Investment firms Therese Liechtenstein joined 4BIO as Investment Director Jupiter Bioventures launches with $70M fund dedicated to biotech startups developing cancer therapeutics or advancing adjacent programs based on cancer biology Media Elizabeth Cairns to join Endpoints as Senior Biopharma Reporter Olivia Freitt has been appointed Editor at European Pharmaceutical Manufacturer Carrie Haslam has been appointed […]
Highlighting Clinical Data and Discovery Platform Following Presentations at EASL Congress 2024 Edinburgh and London, UK, 13 June 2024 – Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company developing macrophage cell therapies to treat end-stage liver disease, today announces that it will host a virtual R&D webinar on Friday 28th June 2024 at 12.30 BST / 7.30 […]
Edinburgh and London, UK, 28 May 2024 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering engineered autologous macrophage cell therapies to transform the treatment of inflammatory organ diseases, today announced that Amir Hefni, Ph.D., Chief Executive Officer, and Simon Ramsden, Chief Financial Officer, will participate in meetings with investors at the […]
Italian investors, NEVA SGR, LIFTT and Simon Fiduciaria, join the existing syndicate Additional investment brings the total Series B financing to £31.1 million (approx. USD $39.5 million) London, UK, 1 February 2024 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces a further extension of £9.6m (approx. USD $12.2m) to its Series B […]
London, UK – 31 October 2023 – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company’s proprietary Lateral CAR platform, today announced that management will be participating in the following upcoming investor conferences during the month of November: BIO-Europe at Messe […]
